Protara Therapeutics (TARA) Competitors $3.46 -0.04 (-1.14%) Closing price 04:00 PM EasternExtended Trading$3.50 +0.04 (+1.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. STOK, MRVI, VERV, GHRS, MNMD, SAGE, UPB, DNA, ABVX, and RGNXShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Stoke Therapeutics (STOK), Maravai LifeSciences (MRVI), Verve Therapeutics (VERV), GH Research (GHRS), Mind Medicine (MindMed) (MNMD), Sage Therapeutics (SAGE), Upstream Bio (UPB), Ginkgo Bioworks (DNA), ABIVAX Société Anonyme (ABVX), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Stoke Therapeutics Maravai LifeSciences Verve Therapeutics GH Research Mind Medicine (MindMed) Sage Therapeutics Upstream Bio Ginkgo Bioworks ABIVAX Société Anonyme REGENXBIO Stoke Therapeutics (NASDAQ:STOK) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Does the MarketBeat Community prefer STOK or TARA? Stoke Therapeutics received 78 more outperform votes than Protara Therapeutics when rated by MarketBeat users. Likewise, 76.28% of users gave Stoke Therapeutics an outperform vote while only 69.49% of users gave Protara Therapeutics an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes11976.28% Underperform Votes3723.72% Protara TherapeuticsOutperform Votes4169.49% Underperform Votes1830.51% Does the media favor STOK or TARA? In the previous week, Protara Therapeutics had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 9 mentions for Protara Therapeutics and 4 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.05 beat Protara Therapeutics' score of 0.44 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, STOK or TARA? Stoke Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Which has better earnings and valuation, STOK or TARA? Protara Therapeutics has lower revenue, but higher earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M14.83-$104.70M-$1.68-5.91Protara TherapeuticsN/AN/A-$40.42M-$2.40-1.45 Do analysts recommend STOK or TARA? Stoke Therapeutics presently has a consensus target price of $24.67, indicating a potential upside of 148.51%. Protara Therapeutics has a consensus target price of $20.40, indicating a potential upside of 486.21%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is STOK or TARA more profitable? Protara Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. Stoke Therapeutics' return on equity of -54.45% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Protara Therapeutics N/A -55.96%-49.06% Do institutionals & insiders have more ownership in STOK or TARA? 38.1% of Protara Therapeutics shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by insiders. Comparatively, 12.5% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryStoke Therapeutics beats Protara Therapeutics on 10 of the 18 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.95M$2.98B$5.53B$7.99BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-1.2330.6422.6518.64Price / SalesN/A500.06401.98103.80Price / CashN/A168.6838.1834.62Price / Book0.583.206.754.30Net Income-$40.42M-$72.35M$3.22B$248.44M7 Day Performance-15.33%1.61%1.66%1.81%1 Month Performance-13.22%8.95%4.17%4.40%1 Year Performance18.77%-22.19%16.17%5.97% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics2.2488 of 5 stars$3.46-1.1%$20.40+489.6%+17.4%$127.21MN/A-1.2330Analyst ForecastNews CoverageSTOKStoke Therapeutics3.512 of 5 stars$9.47-3.0%$24.67+160.5%-11.5%$517.03M$36.56M-4.51100Upcoming EarningsNews CoveragePositive NewsMRVIMaravai LifeSciences4.0285 of 5 stars$2.01-2.0%$6.34+215.6%-75.4%$511.22M$259.19M-1.23610Upcoming EarningsOptions VolumeVERVVerve Therapeutics3.7328 of 5 stars$5.73-0.5%$25.75+349.4%-5.7%$508.80M$32.33M-2.33110Positive NewsGHRSGH Research1.9565 of 5 stars$9.40-1.4%$30.86+228.3%-13.0%$489.06MN/A-11.9010Upcoming EarningsNews CoveragePositive NewsMNMDMind Medicine (MindMed)2.3094 of 5 stars$6.36+2.1%$25.11+294.8%-32.9%$479.34MN/A-2.8140Upcoming EarningsPositive NewsSAGESage Therapeutics3.7284 of 5 stars$7.77-0.3%$8.81+13.4%-47.7%$477.71M$41.24M-1.18690Earnings ReportAnalyst RevisionNews CoverageUPBUpstream BioN/A$8.78+4.6%$56.50+543.5%N/A$471.39M$2.37M0.0038News CoveragePositive NewsDNAGinkgo Bioworks0.6002 of 5 stars$8.02+2.3%$4.58-43.0%-79.3%$465.43M$227.04M-0.61640Upcoming EarningsNews CoverageABVXABIVAX Société Anonyme2.3898 of 5 stars$7.26+6.1%$38.00+423.4%-52.5%$460.42MN/A0.0061Analyst ForecastNews CoveragePositive NewsRGNXREGENXBIO4.4729 of 5 stars$9.13-0.2%$31.63+246.4%-37.4%$457.57M$83.33M-1.82370Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies STOK Alternatives MRVI Alternatives VERV Alternatives GHRS Alternatives MNMD Alternatives SAGE Alternatives UPB Alternatives DNA Alternatives ABVX Alternatives RGNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARA Stock Free TARA Stock Alerts